TP53 and ovarian carcinoma: Paraneoplastic tripartite motif-containing protein 21 (TRIM21) AAbs in combination with anti-New York esophageal squamous cell carcinoma 1 (NY-ESO-1), anti-TP53, and anti-paired box 8 (PAX8, marker of the Fallopian tube secretory cell lineage) AAbs tested in the group of patients with increased risk of ovarian cancer (positive family history, Lynch syndrome, or BRCA germinal mutations) showed 46% sensitivity and 98% specificity.